| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.
|
Eur Heart J
|
2012
|
18.18
|
|
2
|
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.
|
Eur Heart J
|
2013
|
9.54
|
|
3
|
Third universal definition of myocardial infarction.
|
J Am Coll Cardiol
|
2012
|
8.59
|
|
4
|
Third universal definition of myocardial infarction.
|
Circulation
|
2012
|
8.47
|
|
5
|
Third universal definition of myocardial infarction.
|
Eur Heart J
|
2012
|
7.98
|
|
6
|
Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis.
|
JAMA
|
2010
|
1.97
|
|
7
|
Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
|
Eur Heart J
|
2009
|
1.91
|
|
8
|
Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry.
|
Eur Heart J
|
2009
|
1.84
|
|
9
|
Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial.
|
Lancet
|
2012
|
1.80
|
|
10
|
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.
|
Circulation
|
2013
|
1.77
|
|
11
|
Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial.
|
BMJ
|
2011
|
1.74
|
|
12
|
Unprotected left main revascularization in patients with acute coronary syndromes.
|
Eur Heart J
|
2009
|
1.66
|
|
13
|
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial.
|
JACC Cardiovasc Interv
|
2009
|
1.56
|
|
14
|
Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The global registry of acute coronary events.
|
Eur Heart J
|
2009
|
1.53
|
|
15
|
Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease.
|
Am Heart J
|
2010
|
1.53
|
|
16
|
Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery Trial.
|
Eur Heart J
|
2008
|
1.47
|
|
17
|
Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
|
JACC Cardiovasc Interv
|
2013
|
1.46
|
|
18
|
Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE).
|
Am Heart J
|
2003
|
1.29
|
|
19
|
Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes.
|
J Am Coll Cardiol
|
2005
|
1.28
|
|
20
|
Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome.
|
Am Heart J
|
2011
|
1.23
|
|
21
|
Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study.
|
J Am Coll Cardiol
|
2005
|
1.19
|
|
22
|
Relation of mortality of primary angioplasty during acute myocardial infarction to door-to-Thrombolysis In Myocardial Infarction (TIMI) time.
|
Am J Cardiol
|
2003
|
1.19
|
|
23
|
Prehospital Delay in Patients With Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events [GRACE]).
|
Am J Cardiol
|
2009
|
1.18
|
|
24
|
A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial.
|
J Am Coll Cardiol
|
2006
|
1.15
|
|
25
|
ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy.
|
Circulation
|
2011
|
1.13
|
|
26
|
The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.
|
Am Heart J
|
2011
|
1.11
|
|
27
|
Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis.
|
Am J Med
|
2013
|
1.06
|
|
28
|
An international model to predict recurrent cardiovascular disease.
|
Am J Med
|
2012
|
1.02
|
|
29
|
Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry.
|
Eur Heart J
|
2008
|
1.02
|
|
30
|
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.
|
Eur Heart J
|
2012
|
1.02
|
|
31
|
Ethnic differences in cardiovascular risks and mortality in atherothrombotic disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) registry.
|
Mayo Clin Proc
|
2011
|
1.00
|
|
32
|
Renal function, atherothrombosis extent, and outcomes in high-risk patients.
|
Am Heart J
|
2009
|
0.97
|
|
33
|
The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy.
|
J Am Coll Cardiol
|
2011
|
0.94
|
|
34
|
Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry).
|
Am J Cardiol
|
2010
|
0.93
|
|
35
|
Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study.
|
Platelets
|
2013
|
0.91
|
|
36
|
Impact of transradial and transfemoral coronary interventions on bleeding and net adverse clinical events in acute coronary syndromes.
|
EuroIntervention
|
2011
|
0.90
|
|
37
|
Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry.
|
Clin Cardiol
|
2013
|
0.90
|
|
38
|
Fate of individuals with ischemic amputations in the REACH Registry: three-year cardiovascular and limb-related outcomes.
|
Atherosclerosis
|
2012
|
0.87
|
|
39
|
Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH Registry.
|
Vasc Med
|
2010
|
0.86
|
|
40
|
Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.
|
Eur Heart J
|
2008
|
0.85
|
|
41
|
Risk factors and outcomes for patients with vascular disease and serious bleeding events.
|
Heart
|
2011
|
0.84
|
|
42
|
Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.
|
J Am Coll Cardiol
|
2012
|
0.84
|
|
43
|
Thrombocytopenia in patients with an acute coronary syndrome (from the Global Registry of Acute Coronary Events [GRACE]).
|
Am J Cardiol
|
2008
|
0.84
|
|
44
|
Differences in management and outcomes between male and female patients with atherothrombotic disease: results from the REACH Registry in Europe.
|
Eur J Cardiovasc Prev Rehabil
|
2011
|
0.83
|
|
45
|
Global variation in the prevalence of elevated cholesterol in outpatients with established vascular disease or 3 cardiovascular risk factors according to national indices of economic development and health system performance.
|
Circulation
|
2012
|
0.83
|
|
46
|
Impact of chronic kidney disease on use of evidence-based therapy in stable coronary artery disease: a prospective analysis of 22,272 patients.
|
PLoS One
|
2014
|
0.82
|
|
47
|
The future of clinical trials in secondary prevention after acute coronary syndromes.
|
Eur Heart J
|
2010
|
0.81
|
|
48
|
Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group.
|
Am Heart J
|
2009
|
0.80
|
|
49
|
Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute coronary syndrome patients: the Canadian global registry of acute coronary events (GRACE) experience.
|
Am Heart J
|
2009
|
0.80
|
|
50
|
Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian Cohort.
|
Cardiovasc Ther
|
2011
|
0.80
|
|
51
|
Outcomes from the REACH Registry for Australian general practice patients with or at high risk of atherothrombosis.
|
Med J Aust
|
2012
|
0.80
|
|
52
|
Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials.
|
J Thromb Thrombolysis
|
2015
|
0.79
|
|
53
|
Age and lack of beta-blocker therapy are associated with increased long-term mortality after primary coronary angioplasty for acute myocardial infarction.
|
Int J Cardiol
|
2003
|
0.79
|
|
54
|
A history of stroke/transient ischemic attack indicates high risks of cardiovascular event and hemorrhagic stroke in patients with coronary artery disease.
|
Circulation
|
2012
|
0.79
|
|
55
|
Carotid plaque and intima-media thickness and the incidence of ischemic events in patients with atherosclerotic vascular disease.
|
Vasc Med
|
2011
|
0.79
|
|
56
|
Prognostic significance of presenting blood pressure in non-ST-segment elevation acute coronary syndrome in relation to prior history of hypertension.
|
Am Heart J
|
2013
|
0.78
|
|
57
|
The impact of lost therapeutic benefit (LTB) in high-risk hypertensive patients: 2-year follow-up data from the Australian REACH registry.
|
Cardiovasc Ther
|
2013
|
0.78
|
|
58
|
Gender- and age-related differences in clinical presentation and management of outpatients with stable coronary artery disease.
|
Int J Cardiol
|
2012
|
0.78
|
|
59
|
Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial.
|
J Am Coll Cardiol
|
2016
|
0.77
|
|
60
|
Predictors of annual pharmaceutical costs in Australia for community-based individuals with, or at risk of, cardiovascular disease: analysis of Australian data from the REACH registry.
|
Am J Cardiovasc Drugs
|
2010
|
0.77
|
|
61
|
Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitus.
|
Clin Cardiol
|
2012
|
0.76
|
|
62
|
Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: insights from the Global Registry of Acute Coronary Events.
|
Am Heart J
|
2010
|
0.75
|
|
63
|
Circadian variations in outcome of primary percutaneous coronary intervention.
|
J Am Coll Cardiol
|
2003
|
0.75
|
|
64
|
Management and outcomes of patients presenting with STEMI by use of chronic oral anticoagulation: results from the GRACE registry.
|
Eur Heart J Acute Cardiovasc Care
|
2013
|
0.75
|
|
65
|
Usefulness of quantitative versus qualitative ST-segment depression for risk stratification of non-ST elevation acute coronary syndromes in contemporary clinical practice.
|
Am J Cardiol
|
2008
|
0.75
|
|
66
|
Prognostic significance of electrocardiographic-determined left ventricular hypertrophy and associated ST-segment depression in patients with non-ST-elevation acute coronary syndromes.
|
Am Heart J
|
2011
|
0.75
|
|
67
|
Comparative prognostic value of T-wave inversion and ST-segment depression on the admission electrocardiogram in non-ST-segment elevation acute coronary syndromes.
|
Am Heart J
|
2013
|
0.75
|
|
68
|
Cost-effectiveness of optimizing use of statins in Australia: using outpatient data from the REACH Registry.
|
Clin Ther
|
2011
|
0.75
|
|
69
|
Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials.
|
EuroIntervention
|
2017
|
0.75
|
|
70
|
A simple nomogram for early prediction of myocardial reperfusion after pre-hospital thrombolysis.
|
EuroIntervention
|
2011
|
0.75
|
|
71
|
External validation and comparison of formulae estimating 24-h sodium intake from a fasting morning urine sample.
|
J Hypertens
|
2017
|
0.75
|
|
72
|
Outcomes and excess costs among patients with cardiovascular disease.
|
Heart Lung Circ
|
2013
|
0.75
|
|
73
|
"Off-Hours" Versus "On-Hours" Presentation in ST-Segment Elevation Myocardial Infarction: CHAMPION PHOENIX Findings.
|
J Am Coll Cardiol
|
2016
|
0.75
|
|
74
|
Statins in the elderly: what evidence of their benefit in prevention?
|
Arch Cardiovasc Dis
|
2010
|
0.75
|
|
75
|
The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
|
Am Heart J
|
2008
|
0.75
|
|
76
|
Reply: Mean Arterial Pressure Estimation by a Non-Traditional Formula and Fractional Pulse Pressure.
|
J Am Coll Cardiol
|
2016
|
0.75
|